Search

Your search keyword '"Mampreso, Edoardo"' showing total 17 results
Start Over Author "Mampreso, Edoardo"
17 results on '"Mampreso, Edoardo"'

1. Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study

Author

Caponnetto, Valeria, Russo, Antonio, Silvestro, Marcello, Tessitore, Alessandro, De Icco, Roberto, Vaghi, Gloria, Sances, Grazia, Tassorelli, Cristina, Baraldi, Carlo, Castro, Flavia Lo, Guerzoni, Simona, Prudenzano, Maria Pia, Fallacara, Adriana, Gentile, Martino, Ornello, Raffaele, Onofri, Agnese, Burgalassi, Andrea, Chiarugi, Alberto, De Cesaris, Francesco, Granato, Antonio, Casalena, Alfonsina, De Tommaso, Marina, Mampreso, Edoardo, Merlo, Paola, Coppola, Gianluca, Battistini, Stefania, Rebecchi, Valentina, Rainero, Innocenzo, Sepe, Federica Nicoletta, Dalla Volta, Giorgio, Sacco, Simona, Geppetti, Pierangelo, and Iannone, Luigi Francesco

Published
2023
Full Text
View/download PDF

2. Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ)

Author

Onofri, Agnese, Iannone, Luigi Francesco, Granato, Antonio, Garascia, Gabriele, Bartole, Luca, Manganotti, Paolo, Vollono, Catello, Romozzi, Marina, Sottani, Costanza, Calabresi, Paolo, Tassorelli, Cristina, Sances, Grazia, Allena, Marta, De Icco, Roberto, De Cesaris, Francesco, Burgalassi, Andrea, Chiarugi, Alberto, Baraldi, Carlo, Guerzoni, Simona, Prudenzano, Maria Pia, Fallacara, Adriana, Albanese, Maria, Rainero, Innocenzo, Coppola, Gianluca, Casalena, Alfonsina, Mampreso, Edoardo, Pistoia, Francesca, Sarchielli, Paola, Morson, Marisa, Sacco, Simona, Geppetti, Pierangelo, and Ornello, Raffaele

Published
2023
Full Text
View/download PDF

3. Current territorial organization for access to revascularization therapies for acute ischemic stroke in the Veneto region (Italy) from 2017 to 2021

Author

Cappellari, Manuel, Bonetti, Bruno, Baracchini, Claudio, Corbetta, Maurizio, De Boni, Antonella, Critelli, Adriana, Tonello, Simone, Codemo, Valentina, Marcon, Michela, Turinese, Emanuele, Bombardi, Roberto, Basile, Anna Maria, Ruzza, Giampietro, Cadaldini, Morena, Mampreso, Edoardo, Marsala, Sandro Zambito, Padoan, Roberta, Marini, Bruno, Gaudenzi, Anna, Tonon, Agnese, Masato, Maela, Baldi, Antonio, Turazzini, Michelangelo, Zanette, Giampietro, Adami, Alessandro, Saia, Mario, and Bovi, Paolo

Published
2023
Full Text
View/download PDF

4. Correction to: Current territorial organization for access to revascularization therapies for acute ischemic stroke in the Veneto region (Italy) from 2017 to 2021

Author

Cappellari, Manuel, Bonetti, Bruno, Baracchini, Claudio, Corbetta, Maurizio, De Boni, Antonella, Critelli, Adriana, Tonello, Simone, Codemo, Valentina, Marcon, Michela, Turinese, Emanuele, Bombardi, Roberto, Basile, Anna Maria, Ruzza, Giampietro, Cadaldini, Morena, Mampreso, Edoardo, Marsala, Sandro Zambito, Padoan, Roberta, Marini, Bruno, Gaudenzi, Anna, Tonon, Agnese, Masato, Maela, Baldi, Antonio, Turazzini, Michelangelo, Zanette, Giampietro, Adami, Alessandro, Saia, Mario, and Bovi, Paolo

Published
2023
Full Text
View/download PDF

5. Association of anti‐calcitonin gene‐related peptide with other monoclonal antibodies for different diseases: A multicenter, prospective, cohort study.

Author

Iannone, Luigi Francesco, Romozzi, Marina, Russo, Antonio, Saporito, Gennaro, De Santis, Federico, Ornello, Raffaele, Sances, Grazia, Vaghi, Gloria, Tassorelli, Cristina, Albanese, Maria, Guerzoni, Simona, Casalena, Alfonsina, Vollono, Catello, Calabresi, Paolo, Prudenzano, Maria Pia, Mampreso, Edoardo, Volta, Giorgio Dalla, Valente, Maria Rosaria, Avino, Gianluca, and Chiarugi, Alberto

Abstract

Background and purpose: Although there is extensive evidence about the safety of monoclonal antibodies against calcitonin gene‐related peptide (anti‐CGRP mAbs) in combination with traditional drugs, scarce data are available on the safety of their combination with other mAbs. This study aimed to evaluate the 6‐month effectiveness and tolerability of anti‐CGRP mAbs in combination with other mAbs for different diseases. Methods: Patients included in the Italian Headache Registry and treated concomitantly with an anti‐CGRP mAb and another mAb were included. Effectiveness outcomes for migraine included reduction from baseline of monthly headache days (MHDs), Migraine Disability Assessment (MIDAS) score, Headache Impact Test‐6 (HIT‐6) scores, and Patients' Global Impression of Change (PGIC) scale. Adverse events (AEs) were recorded. Results: Thirty‐eight patients were included. In 27 patients (71.1%), the anti‐CGRP mAb was added to a previously ongoing mAb. Nine patients (23.7%) discontinued one of the two mAbs before the end of treatment (seven discontinued the anti‐CGRP mAb and two the other mAb). One patient discontinued for AEs. Anti‐CGRP mAbs were discontinued due to ineffectiveness (n = 5, 55.5%) and one each (11.1%) for clinical remission and lost to follow‐up. MHDs significantly decreased from baseline to 3 months (p < 0.0001) and 6 months (p < 0.001), as did the MIDAS and the HIT‐6 scores at 3 and 6 months (p < 0.001). For anti‐CGRP mAbs, 27.4% of patients reported PGIC ≥ 5 at 3 months and 48.3% at 6 months. Mild AEs associated with introduction of a second mAb were detected in six patients (15.8%). Conclusions: In this real‐world study, anti‐CGRP mAbs showed safety and effectiveness when administered concomitantly with other mAbs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Headache in kidney transplantation

Author

Maggioni, Ferdinando, Mantovan, Maria Cristina, Rigotti, Paolo, Cadrobbi, Roberto, Mainardi, Federico, Mampreso, Edoardo, Ermani, Mario, Cortelazzo, Silvia, and Zanchin, Giorgio

Published
2009
Full Text
View/download PDF

14. Osmophobia in primary headaches

Author

Zanchin, Giorgio, Dainese, Filippo, Mainardi, Federico, Mampreso, Edoardo, Perin, Chiara, and Maggioni, Ferdinando

Subjects
Headache -- Diagnosis, Headache -- Physiological aspects, Neurologic manifestations of general diseases -- Research, Health
Published
2005

17. A prospective study on osmophobia in migraine versus tension-type headache in a large series of attacks.

Author

Terrin, Alberto, Mainardi, Federico, Lisotto, Carlo, Mampreso, Edoardo, Fuccaro, Matteo, Maggioni, Ferdinando, and Zanchin, Giorgio

Subjects
*MIGRAINE, *MIGRAINE aura, *HEADACHE, *LONGITUDINAL method, *BIOMARKERS
Abstract

Background: In literature, osmophobia is reported as a specific migrainous symptom with a prevalence of up to 95%. Despite the International Classification of Headache Disorders 2nd edition proposal of including osmophobia among accompanying symptoms, it was no longer mentioned in the ICHD 3rd edition.Methods: We conducted a prospective study on 193 patients suffering from migraine without aura, migraine with aura, episodic tension-type headache or a combination of these. After a retrospective interview, each patient was asked to describe in detail osmophobia, when present, in the following four headache attacks.Results: In all, 45.7% of migraine without aura attacks were associated with osmophobia, 67.2% of migraineurs reported osmophobia in at least a quarter of the attacks. No episodic tension-type headache attack was associated with osmophobia. It was associated with photophobia or phonophobia in 4.3% of migraine without aura attacks, and it was the only accompanying symptom in 4.7% of migraine without aura attacks. The inclusion of osmophobia in the ICHD-3 diagnostic criteria would enable a 9.0% increased diagnostic sensitivity.Conclusion: Osmophobia is a specific clinical marker of migraine, easy to ascertain and able to disentangle the sometimes challenging differential diagnosis between migraine without aura and episodic tension-type headache. We recommend its inclusion among the diagnostic criteria for migraine as it increases sensitivity, showing absolute specificity. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results